Cancer Research UK & UCL Cancer Trials Centre **CARDAMON** **ADVERSE EVENT FORM**

Trial No: CAR - ☐☐☐ **Initials:** ☐☐☐ **Date of assessment:** ☐☐ ☐☐ ☐☐☐☐ (d d m m y y y y) **Site:** _____

IMPs **Most recent treatment phase:** *(please select one)*

I = Induction
*C = Consolidation **or***
A = ASCT
M = Maintenance
☐

Trial arm:
☐ Consolidation
☐ ASCT
☐ N/A - not yet randomised

Most recent cycle: ☐☐

Adverse Event *(If possible, use term as listed in CTCAE v4.03)*	**Severity Grade** [1] *(Grades 0-5) For grade 0 AEs, do not complete the columns to the right*	**Seriousness Criteria** [2]	**SAE Report Submitted** *0 = No 1 = Yes* [3]	**Dates of Onset** d d m m y y y y *(e.g. 01 – 01 – 2011)*	**Outcome** [4]	**Causal relationship with Carfilzomib**[5]	**Causal relationship with Cyclophosphamide**[5] (N/A in Maintenance unless long term effect)	**Causal relationship with Dexamethasone**[5] (N/A in Maintenance unless long term effect)
Alopecia	☐	☐	Exempt	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Neutrophil count decreased	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Platelet count decreased	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Anemia	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Neuropathy (motor)	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Neuropathy (sensory)	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Diarrhea	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Nausea	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Vomiting	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Fatigue	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
Dizziness	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐

1) Enter worst grade observed during reporting period / Use CTCAE v4.03 where possible
2) Enter code: 0 = not serious; 1 = resulted in death; 2 = life threatening; 3 = required hospitalisation; 4 = resulted in disability/ incapacity; 5 = congenital anomaly or birth defect; 6 = other medically significant
3) If yes, ensure a completed SAE Report has been submitted to the UCL CTC, unless stated in protocol as exempt
4) Enter code: 0 = Fatal; 1 = Not resolved; 2 = Resolved; 3 = Resolved with sequelae; 4 = Resolving; 5 = Unknown
5) Enter code: 0 = Not related (no reasonable possibility) 1 = Related (reasonable possibility)

Cancer Research UK & UCL Cancer Trials Centre	CARDAMON	ADVERSE EVENT FORM

Trial No: CAR - ☐☐☐ **Initials:** ☐☐☐ **Date of assessment:** ☐☐ ☐☐ ☐☐☐☐ (d d m m y y y y) **Site:** ____________________

Adverse Event *(If possible, use term as listed in CTCAE v4.03)*	Severity Grade [1] *(Grades 0-5)* *For grade 0 AEs, do not complete the columns to the right*	Seriousness Criteria [2]	SAE Report Submitted *0 = No* *1 = Yes* [3]	Dates of Onset d d m m y y y y *(e.g. 01 – 01 – 2011)*	Outcome [4]	Causal relationship with Carfilzomib[5]	Causal relationship with Cyclophosphamide[5] (N/A in Maintenance unless long term effect)	Causal relationship with Dexamethasone[5] (N/A in Maintenance unless long term effect)
Back Pain			Exempt	Start End				
Rash pustular				Start End				
Rash acneiform				Start End				
Rash maculo-papular				Start End				
Hypertension				Start End				
Dyspnea				Start End				
Acute kidney injury				Start End				
Lung infection				Start End				
				Start End				
				Start End				
				Start End				
				Start End				
				Start End				

1) Enter worst grade observed during reporting period / Use CTCAE v4.03 where possible
2) Enter code: 0 = not serious; 1 = resulted in death; 2 = life threatening; 3 = required hospitalisation; 4 = resulted in disability/ incapacity; 5 = congenital anomaly or birth defect; 6 = other medically significant
3) If yes, ensure a completed SAE Report has been submitted to the UCL CTC, unless stated in protocol as exempt
4) Enter code: 0 = Fatal; 1 = Not resolved; 2 = Resolved; 3 = Resolved with sequelae; 4 = Resolving; 5 = Unknown
5) Enter code: 0 = Not related (no reasonable possibility) 1 = Related (reasonable possibility)

For UCL CTC use only: Date form received: ________________ Date form checked: ________________ Date form entered: ________________ Initials: __________

Cancer Research UK & UCL Cancer Trials Centre **CARDAMON** **ADVERSE EVENT FORM**

Trial No: CAR - ☐☐☐ **Initials:** ☐☐☐ **Date of assessment:** ☐☐ ☐☐ ☐☐☐☐ (d d m m y y y y) **Site:** ____________________

Adverse Event *(If possible, use term as listed in CTCAE v4.03)*	**Severity Grade** [1] *(Grades 0-5) For grade 0 AEs, do not complete the columns to the right*	**Seriousness Criteria** [2]	**SAE Report Submitted** *0 = No 1 = Yes* [3]	**Dates of Onset** d d m m y y y y *(e.g. 01 – 01 – 2011)*	**Outcome** [4]	**Causal relationship with Carfilzomib**[5]	**Causal relationship with Cyclophosphamide**[5] (N/A in Maintenance unless long term effect)	**Causal relationship with Dexamethasone**[5] (N/A in Maintenance unless long term effect)
	☐	☐	Exempt	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐
	☐	☐	☐	Start ☐☐ ☐☐ ☐☐☐☐ End ☐☐ ☐☐ ☐☐☐☐	☐	☐	☐	☐

1) Enter worst grade observed during reporting period / Use CTCAE v4.03 where possible
2) Enter code: 0 = not serious; 1 = resulted in death; 2 = life threatening; 3 = required hospitalisation; 4 = resulted in disability/ incapacity; 5 = congenital anomaly or birth defect; 6 = other medically significant
3) If yes, ensure a completed SAE Report has been submitted to the UCL CTC, unless stated in protocol as exempt
4) Enter code: 0 = Fatal; 1 = Not resolved; 2 = Resolved; 3 = Resolved with sequelae; 4 = Resolving; 5 = Unknown
5) Enter code: 0 = Not related (no reasonable possibility) 1 = Related (reasonable possibility)

FORM COMPLETED BY: **Print name:** ____________________ **Signature:** ____________________ **Date:** ☐☐ ☐☐ ☐☐☐☐ (*d d m m y y y y*)

Please return to: Cardamon Trial Co-ordinator, CR UK & UCL Cancer Trials Centre, 90 Tottenham Court Road, London, W1T 4TJ, United Kingdom

For UCL CTC use only: Date form received: ____________ Date form checked: ____________ Date form entered: ____________ Initials: ________

Trial No: CAR - ☐☐☐ **Initials:** ☐☐☐ **Date of assessment:** ☐☐ ☐☐ ☐☐☐☐ (d d m m y y y y) **Site:** _____

Completion Instructions

- **Record all adverse events (AEs) that occur from informed consent until 30 days post last trial treatment administration whether related to the trial treatment or not.**
- **Pre-existing events do not qualify as AEs unless they worsen.**
- **All AEs added to the form (not pre-printed) must be added to subsequent forms until they have resolved.**

1) Severity Grade

- Enter worst grade observed since last cycle
- Use CTCAE v4.03 where possible
- If no AE occurred enter "0" and do not complete the columns to the right

2) Seriousness Criteria

- Use the following options: **0 = not serious; 1 = resulted in death; 2 = life threatening; 3 = required hospitalisation; 4 = resulted in disability/ incapacity; 5 = congenital anomaly or birth defect; 6 = other medically significant**

3) SAE Report Submitted

- Ensure a completed SAE Report has been submitted to UCL CTC, unless the event is listed as an SAE reporting exemption in the protocol

4) Outcome

- Use the following options: **0 = Fatal; 1 = Not resolved; 2 = Resolved; 3 = Resolved with sequelae; 4 = Resolving; 5 = Unknown**

5) Causal relationship with

- Use the following options: **0 = "Not related (no reasonable possibility)" 1 = "Related (reasonable possibility)"**

Note: The expression *'reasonable suspected causal relationship'* is meant to convey in general that there is reason (e.g. facts, evidence or arguments) to suggest a causal relationship. Therefore, if you consider an AE to be either *Definitely*, *Probably* or *Possibly* related to the IMP, select *1= Related (reasonable possibility) to a trial treatment*. AEs considered to fall within the *Unlikely* or *None* categories map to *Not related (no reasonable possibility) to a trial treatment*.